Donor haplotype B of NK KIR receptor reduces the relapse risk in HLA-icentical sibling hematopoetic stem cell transplantation of AML patients

Show full item record



Permalink

http://hdl.handle.net/10138/159988

Citation

Impola , U , Turpeinen , H , Alakulppi , N , Linjama , T , Volin , L , Niittyvuopio , R , Partanen , J & Koskela , S 2014 , ' Donor haplotype B of NK KIR receptor reduces the relapse risk in HLA-icentical sibling hematopoetic stem cell transplantation of AML patients ' , Frontiers in Immunology , vol. 5 , 405 . https://doi.org/10.3389/fimmu.2014.00405

Title: Donor haplotype B of NK KIR receptor reduces the relapse risk in HLA-icentical sibling hematopoetic stem cell transplantation of AML patients
Author: Impola, Ulla; Turpeinen, Hannu; Alakulppi, Noora; Linjama, Tiina; Volin, Liisa; Niittyvuopio, Riitta; Partanen, Jukka; Koskela, Satu
Contributor: University of Helsinki, FRC Blood Serv, Res & Dev
University of Helsinki, Department of Medicine
University of Helsinki, Hematologian yksikkö
Date: 2014-08-25
Language: eng
Number of pages: 5
Belongs to series: Frontiers in Immunology
ISSN: 1664-3224
URI: http://hdl.handle.net/10138/159988
Abstract: Successful allogeneic hematopoietic stem cell transplantation (HSCT) depends not only on good HLA match but also on T-cell mediated graft-versus-leukemia (GyL) effect. Natural killer (NK) cells are able to kill malignant cells by receiving activation signal from the killer-cell immunoglobulin-like receptors (KIR) recognizing HLA molecules on a cancer cell. It has been recently reported that the risk of relapse in allogeneic hematopoietic stem cell transplantation (HSCT) is reduced in acute myeloid leukemia (AML) patients whose donors have several activating KIR genes or KIR B-motifs in unrelated donor setting, obviously due to enhanced GyL effect by NK cells. We studied the effect on relapse rate of donor KIR haplotypes in the HLA-identical adult sibling HSCT, done in a single center, in Helsinki University Central Hospital, Helsinki, Finland. Altogether, 134 patients with 6 different diagnoses were identified. Their donors were KIR genotyped using the Luminex and the SSP techniques. The clinical endpoint, that is, occurrence of relapse, was compared with the presence or absence of single KIR genes. Also, time from transplantation to relapse was analyzed. The patients with AML whose donors have KIR2DL2 or KIR2DS2 had statistically significantly longer relapse-free survival (P = 0.015). Our data support previous reports that donors with KIR B-haplotype defining genes have a lower occurrence of relapse in HSCT of AML patients. Determination of donor KIR haplotypes could be a useful addition for a risk assessment of HSCT especially in AML patients.
Subject: NK cells
KIR
HLA
graft versus tumor effect
transplantation immunology
BONE-MARROW-TRANSPLANTATION
ACUTE MYELOGENOUS LEUKEMIA
CYTOMEGALOVIRUS REACTIVATION
HEMATOPOIETIC TRANSPLANTS
FREE SURVIVAL
GENES
POLYMORPHISMS
DIVERSITY
GENOTYPE
MISMATCH
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
fimmu_05_00405.pdf 579.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record